{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:42:33Z","timestamp":1787013753557,"version":"build-2736575974"},"reference-count":13,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,8]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n This study aimed to assess the relationship between immune response adverse events (irAEs) and treatment efficacy in patients with extensive disease small cell lung cancer (ED\u2010SCLC).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We retrospectively evaluated the clinical effects in 40 ED\u2010SCLC patients who had received immune\u2010checkpoint inhibitors (ICIs), platinum agents, and etoposide between September 2019 and September 2021. We identified and compared patients belonging to two groups: irAE and non\u2010irAE.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fifteen patients experienced irAEs, and 25 did not. The median progression\u2010free survival in patients with irAE was longer than that in patients without irAE (12.6\u2009months [95% CI: 6.3\u201319.3\u2009months] vs. 7.2\u2009months [95% CI: 5.8\u20137.9\u2009months],\n p<\/jats:italic>\n \u2009=\u20090.0108). However, the median overall survival (OS) was similar between irAE and non\u2010irAE groups (27.6\u2009months [95% CI: 15.4\u2013NA] vs. 24.9\u2009months [95% CI: 13.7\u2013NA],\n p<\/jats:italic>\n \u2009=\u20090.268). Seven (46.7%) in the irAE group and 20 (80%) in the non\u2010irAE group received sequential therapy. The median OS was prolonged in patients who received first\u2010 and second\u2010line therapy than in those who received first\u2010line therapy alone (27.6\u2009months [95% CI: 19.2\u2013NA] vs. 6.6\u2009months [95% CI: 0.3\u2013NA],\n p<\/jats:italic>\n \u2009=\u20090.053). Grade \u2267 3 irAEs occurred in five (12.5%) patients. Among them, grade 5 irAEs were observed in two patients, including exacerbation of polymyositis and pulmonary arterial embolism.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In this study, the development of irAEs did not affect OS in patients with ED\u2010SCLC who received platinum\u2010based agents, etoposide, or ICI therapy. We determined that managing irAEs and administering first\u2010 and second\u2010line therapies could contribute to prolonged OS.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/1759-7714.15010","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T22:32:36Z","timestamp":1687818756000},"page":"2251-2258","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Relationship between immune\u2010related adverse events and treatment effectiveness in extensive disease small cell lung cancer"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8576-4750","authenticated-orcid":false,"given":"Keiki","family":"Yokoo","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Teine Keijinkai Hospital Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yauo","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Kushiro City General Hospital Kushiro Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Hakodate Goryoukaku Hospital Hakodate Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine Steel Memorial Muroran Hospital Muroran Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Sawai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Kushiro City General Hospital Kushiro Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Honda","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital Infectious Diseases Experts Training Center Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Kushiro City General Hospital Kushiro Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Teine Keijinkai Hospital Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01990"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7711"},{"key":"e_1_2_8_8_1","article-title":"Association between immune\u2010related adverse events and clinical outcomes to programmed cell death protein 1\/programmed death\u2010ligand 1 blockade in SCLC","volume":"1","author":"Ricciuti B","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01549-2"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.07.005"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01899-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.01.013"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01269-9"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T20:40:13Z","timestamp":1691959213000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":13,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/1759-7714.15010"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15010","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"2023-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}